Wednesday, 18 March 2009
ECU and Perth-based pharmaceutical company Alzhyme Limited have joined forces to help advance the diagnosis and treatment of Alzheimer's disease.
This exciting new partnership will allow new research developments at ECU to move into commercialisation.
The license and option agreement gives Alzhyme the first option to license new Intellectual Property for commercialisation in the field of diagnosis and treatment of Alzheimer's disease.
Alzhyme will also have the option to fund new projects on a commercial basis, either exclusively or in partnership with ECU.
ECU Deputy Vice-Chancellor (Research), Professor John Finlay-Jones says the partnership will allow ECU to continue to further the understanding of Alzheimer's disease through research.
"Research partnerships such as this one are critical to the advancement of medical research and will hopefully one day lead to the effective treatment of this debilitating disease," he says.